Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAC vs ACAC +/- Trastuzumab as Neoadjuvant Therapy for Stage II-III Breast Cancer
NCT00295893Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Sep 2005
- Primary completion
- Dec 2013
- Modality
- Polymer-based Nanoparticles, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, pegylated liposomal doxorubicin, cyclophosphamide, Paclitaxel Micelles for Injection, carboplatin in breast cancer, sponsored by City of Hope. Started Sep 2005; status: active, not recruiting.
02
Drugs
docetaxelpegylated liposomal doxorubicincyclophosphamidePaclitaxel Micelles for Injectioncarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00295893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00295893.